Literature DB >> 19170400

Partial remission, residual symptoms, and relapse in depression.

E S Paykel1.   

Abstract

Partial remission from depression, with residual symptoms, is an important problem in depression. This paper reviews the frequency and features of this outcome, and its association with relapse. Residual symptoms occur in many depressed patients after acute treatment. They span the typical symptoms of depression, except those characteristic of severe disorders. Other persistent abnormalities include social dysfunction, dysfunctional attitudes, hypothalamic-pituitary-adrenal axis overactivity, shortened REM sleep latency, and mood lowering after tryptophan depletion. Associations of some of these with residual symptoms are not clear. There is growing evidence for similar residual symptoms in bipolar disorder, particularly bipolar depression. The most important consequence of residual symptoms is a much-increased risk of relapse, particularly in the first year. Residual symptoms are a strong indication for vigorous and longer than usual continuation of antidepressant treatment in order to prevent relapse. There is good evidence for the use of cognitive therapy as an adjunct.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19170400      PMCID: PMC3181895     

Source DB:  PubMed          Journal:  Dialogues Clin Neurosci        ISSN: 1294-8322            Impact factor:   5.986


  68 in total

1.  DST abnormality as a predictor of course in major depression.

Authors:  W Coryell
Journal:  J Affect Disord       Date:  1990-07       Impact factor: 4.839

2.  Social adjustment and depression. A longitudinal study.

Authors:  E S Paykel; M M Weissman
Journal:  Arch Gen Psychiatry       Date:  1973-05

3.  Continuation drug therapy for major depressive episodes: how long should it be maintained?

Authors:  R F Prien; D J Kupfer
Journal:  Am J Psychiatry       Date:  1986-01       Impact factor: 18.112

4.  Dexamethasone suppression test as indicator of safe withdrawal of antidepressant therapy.

Authors:  I K Goldberg
Journal:  Lancet       Date:  1980-02-16       Impact factor: 79.321

5.  Refractory depression: prediction of non-response by clinical indicators.

Authors:  D J Kupfer; D G Spiker
Journal:  J Clin Psychiatry       Date:  1981-08       Impact factor: 4.384

6.  Normalization of dexamethasone suppression test: a laboratory index of recovery from endogenous depression.

Authors:  J F Greden; A A Albala; R F Haskett; N M James; L Goodman; M Steiner; B J Carroll
Journal:  Biol Psychiatry       Date:  1980-06       Impact factor: 13.382

7.  Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

Authors:  E Frank; R F Prien; R B Jarrett; M B Keller; D J Kupfer; P W Lavori; A J Rush; M M Weissman
Journal:  Arch Gen Psychiatry       Date:  1991-09

8.  Personality and the prediction of long-term outcome of depression.

Authors:  M M Weissman; B A Prusoff; G L Klerman
Journal:  Am J Psychiatry       Date:  1978-07       Impact factor: 18.112

9.  Prediction of outcome in depressed patients by weekly monitoring with the dexamethasone suppression test.

Authors:  I Schweitzer; K P Maguire; A H Gee; J W Tiller; N Biddle; B Davies
Journal:  Br J Psychiatry       Date:  1987-12       Impact factor: 9.319

10.  Persistent cortisol non-suppression after clinical recovery predicts symptomatic relapse in unipolar depression.

Authors:  G A Charles; M Schittecatte; A J Rush; M Panzer; J Wilmotte
Journal:  J Affect Disord       Date:  1989 Nov-Dec       Impact factor: 4.839

View more
  34 in total

1.  STAR*D and Measurement-Based Care for Depression: Don't Toss Out the Baby!

Authors:  Raymond W Lam; Sidney H Kennedy
Journal:  Can J Psychiatry       Date:  2015-01       Impact factor: 4.356

2.  Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and meta-synthesis.

Authors:  J E J Buckman; A Underwood; K Clarke; R Saunders; S D Hollon; P Fearon; S Pilling
Journal:  Clin Psychol Rev       Date:  2018-07-29

3.  The Ethics of Clinical Trials Research in Severe Mood Disorders.

Authors:  Allison C Nugent; Franklin G Miller; Ioline D Henter; Carlos A Zarate
Journal:  Bioethics       Date:  2017-05-15       Impact factor: 1.898

4.  Depression, telomeres and mitochondrial DNA: between- and within-person associations from a 10-year longitudinal study.

Authors:  J E Verhoeven; D Révész; M Picard; E E Epel; O M Wolkowitz; K A Matthews; B W J H Penninx; E Puterman
Journal:  Mol Psychiatry       Date:  2017-03-28       Impact factor: 15.992

5.  Electroacupuncture for residual insomnia associated with major depressive disorder: a randomized controlled trial.

Authors:  Wing-Fai Yeung; Ka-Fai Chung; Kwok-Chu Tso; Shi-Ping Zhang; Zhang-Jin Zhang; Lai-Ming Ho
Journal:  Sleep       Date:  2011-06-01       Impact factor: 5.849

6.  Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism mediates inflammation-induced deficit in recognition memory.

Authors:  Jillian M Heisler; Jason C O'Connor
Journal:  Brain Behav Immun       Date:  2015-06-27       Impact factor: 7.217

Review 7.  Top-Down Control of Serotonin Systems by the Prefrontal Cortex: A Path toward Restored Socioemotional Function in Depression.

Authors:  Collin Challis; Olivier Berton
Journal:  ACS Chem Neurosci       Date:  2015-03-17       Impact factor: 4.418

8.  Continuity and stability of preschool depression from childhood through adolescence and following the onset of puberty.

Authors:  Michael S Gaffrey; Rebecca Tillman; Deanna M Barch; Joan L Luby
Journal:  Compr Psychiatry       Date:  2018-07-25       Impact factor: 3.735

9.  Predictors of Rehospitalization for Depressed Adolescents Admitted to Acute Psychiatric Treatment.

Authors:  Nienke R van Alphen; Jeremy G Stewart; Erika C Esposito; Bryan Pridgen; Joseph Gold; Randy P Auerbach
Journal:  J Clin Psychiatry       Date:  2017-05       Impact factor: 4.384

10.  Safety of research into severe and treatment-resistant mood disorders: analysis of outcome data from 12 years of clinical trials at the US National Institute of Mental Health.

Authors:  Allison C Nugent; Nicolas D Iadarola; Frank G Miller; David A Luckenbaugh; Carlos A Zarate
Journal:  Lancet Psychiatry       Date:  2016-03-10       Impact factor: 27.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.